Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
Executive Summary
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.
You may also be interested in...
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Bristol’s Bold Projections Grow Bolder As Confidence In R&D Programs Rises
Loss of exclusivity for key Bristol Myers Squibb products, starting with top seller Revlimid, is looming over the company’s R&D pipeline. BMS believes its late-stage and newly approved products will generate more than $25bn in sales by 2029.
Sandoz Defeat On Amgen’s Otezla Pushes US Generic Opportunity Back To 2028
Amgen is set to enjoy its monopoly on the Otezla oral treatment for plaque psoriasis until late into the decade, after ANDA sponsors Sandoz and Zydus Cadila failed to find a way around the originator’s intellectual property, including a key patent expiring early in 2028.